First-line antipsychotics
Selected for cardiometabolic profile, per the RANZCP/ANZJP 2026 GRADE guideline.
1Aripiprazole: D2 partial agonist — lowest weight gain among the options, PBS-funded; watch for akathisia and insomnia.
2Brexpiprazole: D2 partial agonist — newer, generally well tolerated; watch for akathisia and (lesser) weight gain.
3Cariprazine: D2/D3 partial agonist — relatively favoured for negative symptoms; watch for akathisia and extrapyramidal symptoms.
4Lurasidone: D2 antagonist — low weight gain, but must be taken with food (around 350 calories) for adequate absorption; watch for akathisia.
Other options. Risperidone — older first-line option, available as a long-acting injectable; watch for hyperprolactinaemia and extrapyramidal symptoms. Olanzapine — often highly effective, but carries higher metabolic risk; consider co-commencing metformin; watch for weight gain, dyslipidaemia and type 2 diabetes. Quetiapine — sedating, sometimes used off-label for sleep or anxiety; watch for sedation, metabolic effects and postural hypotension.